In clinical trials, adults who used Wegovy alongside diet and lifestyle changes lost an average of 1415% of their body weight over one year.* Individual results vary based on factors such as dosage, adherence, lifestyle habits, and overall health
The following GLP-1 (glucagon-like peptide-1) receptor agonists are FDA-approved for weight loss:[ref] Retatrutide is a GLP-1/GIP/GCG triple agonist that is currently in trials for weight loss and diabetes, showing promise for weight loss without muscle loss (2026)
American Diabetes Association, Grant/Award Number: 1-17-ICTS-059 Footnotes DISCLOSURE None declared
SGLT-2 inhibitors and GLP-1RA should, therefore, be considered evidence-based treatments for patients with type 2 diabetes after metformin
If you notice hardness or dimpling, immediately switch to a different body region
Current status: Phase 3 trials (expected to continue through 2025-2026) FDA approval timeline: Likely 2026-2027 at the earliest What needs to happen first: Complete Phase 3 trials in larger populations Gather long-term safety data FDA review and approval process Manufacturing scale-up So while the results are exciting, we're still a few years away from retatrutide being available by prescription
